In The News
Check Out Tixel News
The Balancing Act Features Tixel i for Dry Eye Relief
Hear expert insights from Dr. April Jasper from Advanced Eye Care Specialists in South Florida and Dr. Lauren Bailey at West Plano Dry Eye and Aesthetics as they break down dry eye and its most common cause — Meibomian Gland Dysfunction (MGD).
Discover effective, long-term solutions beyond just drops!
Discover How Tixel Is Transforming Dry Eye Relief
In this recent USA Today spotlight, learn how Tixel’s innovative 2-minute treatment is offering long-lasting relief for dry eye sufferers—and why eye care practices across the country are rapidly adopting it. From patient success stories to clinical insights, this feature explores the science and simplicity behind Tixel’s impact..
Novoxel and GPOphtho Partner to Expand Access to Dry Eye and Aesthetic Treatments
Novoxel Inc. and GPOphtho have announced a strategic partnership to bring Novoxel’s FDA-cleared Tixel® devices, including the rapid, non-invasive Tixel i® for dry eye and aesthetic treatments, to eyecare providers nationwide—offering discounted pricing and innovative, consumable-free technology.
New York Ophthalmologist Sees Rapid Growth with Tixel i® Dry Eye Treatment
Dr. Noaman Sanni of Center for Sight New York has experienced significant patient and revenue growth after integrating Tixel i®, Novoxel’s FDA-cleared device for Meibomian Gland Dysfunction (MGD), into his practice. Within two months, over 225 patients received the quick, non-invasive treatment, which delivers lasting relief in under two minutes without the need for anesthesia or consumables. Dr. Debra Koloms, the clinic’s medical director, praised Tixel i® as “the most impressive treatment” she has encountered in 40 years of practice.
Tixel i® Shows Sustained Relief for Dry Eye Patients
A recent study published in JOJ Ophthalmology confirms that Novoxel’s FDA-cleared Tixel i® device delivers long-lasting improvements for patients with evaporative dry eye disease caused by Meibomian Gland Dysfunction (MGD). The non-invasive treatment significantly enhanced clinical measures like Tear Break-Up Time and Meibomian Gland Scores, while reducing Ocular Surface Disease Index scores—all without adverse effects. Real-world results at West Plano Dry Eye & Aesthetics echoed the findings, with patients reporting meaningful symptom relief in under two minutes per session. Dr. Lauren Bailey praised Tixel i® as a breakthrough for patients who had exhausted other options.
